Invokana 300 mg and 100 mg tablet

DRUG2 trials

Sponsors

McGill University Health Centre/Research Institute of the McGill University Health Centre, University Medical Center Groningen

Conditions

CKD Stage 4CKD Stage 5Chronic Kidney Disease (Stages 4 and 5)DialysisESRD

Phase 4

Safety and Efficacy of Canagliflozin in Advanced CKD

CompletedNCT05309785

McGill University Health Centre/Research Institute of the McGill University Health CentreCKD Stage 4, CKD Stage 5, ESRD

Start: 2022-11-24End: 2026-07-01Updated: 2026-07-13

CANagliflozin In DIALysis Patients

Not yet recruitingNCT07527390

University Medical Center GroningenChronic Kidney Disease (Stages 4 and 5), Dialysis

Start: 2026-06-01End: 2027-01-30Target: 10Updated: 2026-05-06

Related Papers

Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney Disease.

2025-09-15